SCOLI Pro Epigenetics: Scoliosis test

What is SCOLI PRO Epigenetics?

Plan the most effective treatments for adolescent scoliosis.

SCOLI PRO Genetics is an epigenetic test developed in conjunction with EpiDisease, an investee company of ARQUIMEA, enabling to improve the monitoring and planning of treatments for Adolescent Idiopathic Scoliosis (AIS).

The AIS is a multifactorial disease in which both the individual’s genetics and the environmental factors, known as epigenetics, contribute to its onset and progression. Therefore, the early diagnosis is basic to avoid worsening of this pathology in adolescents.

The SCOLI PRO test identifies genetic and epigenetic biomarkers which allow to predict the response of the patient to a brace-based treatment, for example, enabling the doctor to plan the most effective treatments.

Find out SCOLI PRO

Early detection of scoliosis through epigenetics

Monitoring of the disease using a non-invasive test

SCOLI PRO detects epigenetic factors allowing to evaluate the prognoses of the disease using a simple blood test.

It reduces the number of radiographs

It reduces the number of X-ray tests taken by patients, as well as the risk of developing cancer due to the prolonged exposure to X-rays.

Along with traumatologists

We work along with benchmark traumatologists and hospitals, such as the Hospital Universitario y Politécnico La FE in Valencia, testing the test in affected patients.